Recent Updates
Recently added Catalysts
TFX Positive Sentiment

Teleflex Announces Second Quarter 2026 Earnings Conference Call Information

Thursday, July 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Teleflex Incorporated will hold a conference call on August 6, 2026, to discuss its second quarter financial results and provide an operational update. The call will begin at 8:00 a.m. Eastern Time and will be accessible via a pre-registration link and a live audio webcast on the company's website. An audio replay will be available after the call.
Price reaction · baseline $134.8 (2026-07-22 close) · hit pre-market · clean, no other TFX news in the window
day 0 close · peak
-2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Teleflex is actively engaging with investors through a conference call.
  • The call will provide operational updates and financial results.
  • The event is scheduled at a convenient time for participants.

Full Press Release Details

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 6, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com. An audio replay of the call will be available beginning

Frequently Asked Questions

When is the Teleflex Q2 2026 earnings call?

The earnings call is scheduled for August 6, 2026, at 8:00 a.m. Eastern Time.

How can I participate in the Teleflex earnings call?

Participants can pre-register to receive dial-in information or access the call via a live audio webcast.

Will there be a replay of the earnings call?

Yes, an audio replay of the call will be available after the event.

ShareAdd on Google
Tags: TFX Teleflex Q2 2026 earnings call financial results operational update
Last updated: Jul 23, 2026

Biotech snapshot

Cash runway
$327M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Arterial SealingPhase 3
Hemostasis of Arterial Punctures →